Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV.
Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV.
复制标题
DOI：
10.2147/dddt.s84850
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Walmsley SL
中科院分区：
文献类型：
--
作者：
Kandel CE;Walmsley SL
Dolutegravir是最新被批准用于治疗人类免疫缺陷病毒（HIV）感染的整合酶链转移抑制剂。对于treatment-naïve和有治疗经验的患者，包括既往有雷替韦韦或艾替韦韦失败的患者，Dolutegravir与现有治疗方案相当或优于现有治疗方案。一致的疗效加上良好的耐受性和很少的药物-药物相互作用使得多替格拉韦与两种核苷酸逆转录酶抑制剂联合制剂成为一种有吸引力的治疗选择。本文综述了多替格拉韦治疗HIV的药代动力学、不良事件概况和疗效。
Dolutegravir is the newest integrase strand transfer inhibitor to be approved for the treatment of human immunodeficiency virus (HIV) infection. Dolutegravir is equivalent or superior to existing treatment regimens in both treatment-naïve and treatment-experienced patients including those with previous raltegravir or elvitegravir failure. The consistent efficacy coupled with excellent tolerability and infrequent drug–drug interactions makes the co-formulation of dolutegravir with two nucleotide reverse-transcriptase inhibitors an attractive treatment option. This review summarizes the pharmacokinetics, adverse event profile, and efficacy of dolutegravir in the treatment of HIV.